Hepatitis: Yokosuka O

Yokosuka O. · Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ward, Chiba City, Chiba 260-8670, Japan. · Hepatol Res. · Pubmed #15869903 No free full text.

This publication has no abstract.

Yokosuka O. · Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ward, Chiba City, Chiba 260-8670, Japan. · Hepatol Res. · Pubmed #15862782 No free full text.

This publication has no abstract.

Yokosuka O. · No affiliation provided · J Gastroenterol. · Pubmed #15338383 No free full text.

This publication has no abstract.

Yokosuka O, Arai M. · Department of Medicine and Clinical Oncology, K1, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chiba, 260-8670, Japan. · Med Mol Morphol. · Pubmed #16998621 No free full text.

Abstract: Hepatitis B virus (HBV) is a major cause of liver disease worldwide. It is covered with envelope (surface antigen) proteins with the nucleocapsid (core antigen) inside. In the nucleocapsid, there is an incomplete double-stranded DNA and a DNA polymerase. Four genes, S, C, X, and P, are encoded, and these partially overlap. Mutations have been reported in each gene and in their promoter regions, and these mutations can change the efficiency of HBV replication and the clinical course of patients. In this article, we review the relationship between the molecular biology of HBV and its clinical outcome.

Kurihara T, Mikata R, Yokosuka O. · Department of Medicine and Clinical Oncology, Graduate School of Medicine Chiba University. · Nippon Rinsho. · Pubmed #16838658 No free full text.

Abstract: Long-term interferon therapy is an alternative therapy for patients with chronic hepatitis C who can not tolerate to the combination of pegylated interferon and ribavirin. In 2005, self-injection of interferon for chronic hepatitis C was covered by public health insurance in Japan making the long-term interferon therapy easier to perform. For the safe performance of self-injection, education about knowledge on various adverse effects of interferon, training for actual performance of self-injection, and close contact between the patients and doctors are indispensable. In this review, we briefly summarized why self-injection is needed and how the training for safe self-injection of interferon should be performed.

Fujiwara K, Yokosuka O. · Department of Internal Medicine, Kawatetsu Chiba Hospital. · Nippon Rinsho. · Pubmed #16111285 No free full text.

This publication has no abstract.

Kanda T, Yokosuka O, Hirasawa Y, Imazeki F, Nagao K, Suzuki Y, Saisho H. · First Department of Internal Medicine, Chiba University School of Medicine, Chiba, Japan. · Hepatogastroenterology. · Pubmed #16001669 No free full text.

Abstract: We report a 54-year-old Japanese man, whose ALT level was 1689 IU/L, without increased gamma-globulin level or autoantibodies. He could not be diagnosed as autoimmune hepatitis (AIH) using scoring systems, and his liver function became normalized after steroid treatment. Recently, AIH with acute presentation of disease and acute-onset AIH without bridging fibrosis have been increasingly reported but cases without the character of increasing gamma-globulin level or autoantibodies before immunosuppressive treatment are extremely rare. This is the third such case report in the literature.

Kojima H, Yokosuka O. · Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University. · Nippon Rinsho. · Pubmed #15453392 No free full text.

This publication has no abstract.

Fujiwara K, Yokosuka O. · Department of Internal Medicine, Kawatetsu Chiba Hospital. · Nippon Rinsho. · Pubmed #15453365 No free full text.

This publication has no abstract.

Fujiwara K, Yokosuka O. · Department of Internal Medicine, Kawatetsu Chiba Hospital. · Nippon Rinsho. · Pubmed #15453361 No free full text.

This publication has no abstract.

Kanda T, Nagao K, Yokosuka O, Imazeki F. · Health Sciences Center, Chiba University. · Nippon Rinsho. · Pubmed #15453326 No free full text.

This publication has no abstract.

Yokosuka O, Fukai K. · Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University. · Nippon Rinsho. · Pubmed #15453282 No free full text.

This publication has no abstract.

Honda A, Yokosuka O. · Department of Gastroenterology, Saiseikai Narashino Hospital. · Nippon Rinsho. · Pubmed #15453281 No free full text.

This publication has no abstract.

Yokosuka O, Mikata R. · Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University. · Nippon Rinsho. · Pubmed #15359821 No free full text.

This publication has no abstract.

Tanaka M, Yokosuka O, Omata M. · Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University. · Nippon Rinsho. · Pubmed #15359761 No free full text.

This publication has no abstract.

Fujiwara K, Yokosuka O. · Department of Internal Medicine, Kawatetsu Chiba Hospital. · Nippon Rinsho. · Pubmed #12718037 No free full text.

This publication has no abstract.

Yokosuka O, Chiba T. · Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University. · Nippon Rinsho. · Pubmed #11762001 No free full text.

This publication has no abstract.

Sumi H, Yokosuka O. · Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University. · Nippon Rinsho. · Pubmed #11761989 No free full text.

This publication has no abstract.

Yokosuka O. · No affiliation provided · Nippon Naika Gakkai Zasshi. · Pubmed #11215473 No free full text.

This publication has no abstract.

Yokosuka O. · First Department of Medicine, Chiba University School of Medicine, Japan. · J Gastroenterol Hepatol. · Pubmed #10921381 No free full text.

Abstract: Chronic hepatitis B is the result of the immunological response of the host to persistently replicating hepatitis B virus. Steroids can modulate this response; after steroid administration, viral replication increases and after drug withdrawal, it decreases in conjunction with a temporal increase in the transaminase level. Long-term decrease of the viral level is observed in some patients, but the beneficial effect of steroid withdrawal alone has not been confirmed. Interferon and other anti-viral agents can suppress virus replication, but the effect of these agents is still unsatisfactory. The combination of steroid priming and anti-viral treatment may be beneficial. Recent large-scale controlled trials indicate the utility of the combination therapy, but other randomized trials show no significant difference between therapy with or without steroid priming. Although steroid priming in combination with antiviral agents may be useful in some patients, it should be carefully performed due to the potential risk of liver failure.

Yokosuka O. · First Department of Medicine, Chiba University School of Medicine, Japan. · J Gastroenterol Hepatol. · Pubmed #10759226 No free full text.

Abstract: Hepatitis A virus (HAV) is the sole member of the hepatogenus of Picorna viridae. This virus can now be propagated in cell culture and in primates. Molecular biological studies of HAV have disclosed its genomic structure and the functional significance of the viral proteins to some extent. Hepatitis A virus has a positive-stranded RNA of approximately 7.5 kb that encodes a large polyprotein. Translation of the protein is influenced by the function of the internal ribosomal entry site in the 5' non-translating region. It is generally agreed that the polyprotein is processed to four structural and seven non-structural proteins by the proteinase encoded in the 3C region. Replication efficiency seems to be controlled by amino acid substitutions in the 2B and 2C regions. The virulence of HAV in primates may be determined by substitutions in the 2C region. Although the severity of hepatitis A was thought to be determined by immunological reactions of the host to the virus, the potential virulence of the variant viruses themselves may need further examination. Recent progress in polymerase chain reaction technology has made possible an analysis of the HAV sequence in clinical specimens; such analysis is of importance in the disclosure of differences in HAV subspecies in different clinical conditions.

Kanda T, Yokosuka O. · First Department of Medicine, Chiba University School of Medicine. · Nippon Rinsho. · Pubmed #10390993 No free full text.

Abstract: It has been clarified that hepatitis G/GB virus-C is the minor cause of acute and chronic non-A-E hepatitis. But there exist non-A-E viral hepatitis patients. Recently, one of non-A-E hepatitis associated virus was identified and the new virus was named TT virus. We highly detected TT virus in the serum of hepatitis patients. TT virus were reported to be detected 1-37% of the general population in the world. TT virus may account for only a minor part of acute non-A-E hepatitis in Japan. However, whether TT virus infection really causes severe acute hepatitis is required to be elucidated.

Seta T, Yokosuka O. · First Department of Medicine, Chiba University School of Medicine. · Nippon Rinsho. · Pubmed #10390988 No free full text.

Abstract: Recently, a novel hepatitis related virus was described and named as TTV. The positive rates of TTV DNA in healthy subjects to far reported ranged from 1% to 62%, therefore, there must be large differences in the prevalence of TTV in healthy subjects from country to country. However, detailed data are lacking in many reports, care should be taken in analyzing them. Generally, elderly subjects tend to have increased positivity in the same area. Sanitary environment may influence the positive rate. In addition the distribution of genotype may influence the positive rate. Although the high prevalence of TTV in healthy subjects may indicate the TTV as non-hepatopathogenic virus, further studies will be needed before drawing the conclusion.

Kobashi H, Takaguchi K, Ikeda H, Yokosuka O, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Sakaguchi K, Shiratori Y. · Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. · J Gastroenterol Hepatol. · Pubmed #19215336 No free full text.

Abstract: BACKGROUND AND AIM: Entecavir has demonstrated clinical efficacy for chronic hepatitis B. This study evaluated the efficacy and safety of entecavir in nucleoside-naive Japanese chronic hepatitis B patients. METHODS: In this multicenter, double-blind study, 66 nucleoside-naive Japanese chronic hepatitis B patients were randomized to 0.1 mg entecavir (n = 32) or 0.5 mg entecavir (n = 34) daily for 52 weeks. The primary endpoint was the proportion of patients whose serum hepatitis B virus (HBV) DNA decreased from baseline by > or =2 log(10) copies/mL or became undetectable (<400 copies/mL by polymerase chain reaction assay) at week 48. RESULTS: One hundred percent of patients in both treatment groups achieved the primary efficacy endpoint, with 81% and 68% of patients achieving undetectable HBV DNA in the 0.1 mg and 0.5 mg treatment groups, respectively. Mean changes from baseline in HBV DNA were -4.49 log(10) and -4.84 log(10) copies/mL for the 0.1 mg and 0.5 mg groups, respectively. Significant improvements in necroinflammation were seen in both groups, as assessed by Knodell and New Inuyama classifications. Most adverse events were transient and classified as grade 1 or 2. There were no clinically significant differences in adverse events across the two treatment groups and no discontinuations due to adverse events in either group. CONCLUSIONS: In Japanese nucleoside-naive patients with chronic hepatitis B, 0.1 mg or 0.5 mg entecavir daily provided excellent efficacy and was well tolerated. The 0.5 mg dose was selected for the treatment of nucleoside-naive patients.

Fujiwara K, Yokosuka O, Komine F, Moriyama M, Kato N, Yoshida H, Tanaka N, Imazeki F, Shiratori Y, Arakawa Y, Omata M, Anonymous00363. · Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan. · Liver Int. · Pubmed #16761995 No free full text.

Abstract: BACKGROUND: Hepatitis C virus (HCV) RNA titer and HCV genotype are two major determinants of the outcome of interferon (IFN) monotherapy. To clarify the usefulness of combination therapy with IFN and ribavirin in Japanese hepatitis C patients, we treated patients with a relatively high dose of IFN in combination with ribavirin for 24 weeks and examined the effects in relation to the viral parameters. METHODS: Two hundred and ninety-five patients were enrolled in the study. The patients received either 6 or 10 million units (MU) of interferon alpha-2b every day for 2 weeks and then three times a week for 22 weeks with a daily dose of either 600 or 800 mg of ribavirin. The treatment response and safety of this treatment were examined. RESULTS: The sustained virologic response (SVR) rates were 26.8% in genotype 1 and 76.5% in genotype 2 (P < 0.001), and 36.1% with the 6 MU group and 45.8% with the 10 MU group (P = 0.09). Multivariate analysis indicated that SVR was associated with genotype 2, HCV RNA <500 kilointernational unit/ml (kIU/ml), and HCV RNA undetectability at week 8 of treatment. CONCLUSION: Our current study showed that a 24-week course of IFN plus ribavirin combination therapy was effective with respect to virologic response in Japanese hepatitis C patients, particularly in patients with HCV genotype 2.